Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Other Non-Current Liabilities of $119.0 million for Q1 2026, down 28.31% year-over-year from $166.0 million in Q1 2025, and down 11.85% quarter-over-quarter from $135.0 million in Q4 2025.
Arcus Biosciences (RCUS) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Arcus Biosciences' Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $119.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 28.31% year-over-year to $119.0 million; the TTM figure through Mar 2026 stood at $119.0 million (down 28.31% YoY), while the FY2025 annual figure was $135.0 million, down 14.01% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $119.0 million, down from $135.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $166.0 million in Q1 2025, with the low at $13.9 million in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $140.0 million (2022), against an average of $121.3 million.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities soared 945.12% in 2023, then decreased 28.31% in 2026.
- Arcus Biosciences' Other Non-Current Liabilities stood at $140.0 million in 2022, then climbed by 1.43% to $142.0 million in 2023, then increased by 10.56% to $157.0 million in 2024, then declined by 14.01% to $135.0 million in 2025, then dropped by 11.85% to $119.0 million in 2026.
- Business Quant data shows RCUS's Other Non-Current Liabilities at $119.0 million in Q1 2026, $135.0 million in Q4 2025, and $152.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.00 Mn |
| Mar 31, 2026 | 119.00 Mn |
| Dec 31, 2025 | 135.00 Mn |
| Sep 30, 2025 | 152.00 Mn |
| Jun 30, 2025 | 159.00 Mn |
| Mar 31, 2025 | 166.00 Mn |
| Dec 31, 2024 | 157.00 Mn |
| Sep 30, 2024 | 136.00 Mn |
| Jun 30, 2024 | 138.00 Mn |
| Mar 31, 2024 | 140.00 Mn |
| Dec 31, 2023 | 142.00 Mn |
| Sep 30, 2023 | 145.00 Mn |
| Jun 30, 2023 | 144.00 Mn |
| Mar 31, 2023 | 145.00 Mn |
| Dec 31, 2022 | 140.00 Mn |
| Sep 30, 2022 | 16.17 Mn |
| Jun 30, 2022 | 14.68 Mn |
| Mar 31, 2022 | 13.87 Mn |
| Dec 31, 2021 | 122.00 Mn |
| Sep 30, 2021 | 10.20 Mn |